NZ701693A - Composition and methods for highly efficient gene transfer using aav capsid variants - Google Patents
Composition and methods for highly efficient gene transfer using aav capsid variantsInfo
- Publication number
- NZ701693A NZ701693A NZ701693A NZ70169313A NZ701693A NZ 701693 A NZ701693 A NZ 701693A NZ 701693 A NZ701693 A NZ 701693A NZ 70169313 A NZ70169313 A NZ 70169313A NZ 701693 A NZ701693 A NZ 701693A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methods
- aav
- composition
- gene transfer
- highly efficient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261635273P | 2012-04-18 | 2012-04-18 | |
| US201361794995P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/037170 WO2013158879A1 (en) | 2012-04-18 | 2013-04-18 | Composition and methods for highly efficient gene transfer using aav capsid variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ701693A true NZ701693A (en) | 2017-02-24 |
Family
ID=49384070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ701693A NZ701693A (en) | 2012-04-18 | 2013-04-18 | Composition and methods for highly efficient gene transfer using aav capsid variants |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9909142B2 (online.php) |
| EP (1) | EP2839014B1 (online.php) |
| JP (1) | JP6342886B2 (online.php) |
| KR (1) | KR102063483B1 (online.php) |
| CN (1) | CN104487579B (online.php) |
| AU (1) | AU2013249202B2 (online.php) |
| BR (2) | BR122021020419B1 (online.php) |
| CA (1) | CA2870736C (online.php) |
| CO (1) | CO7200251A2 (online.php) |
| DK (1) | DK2839014T3 (online.php) |
| ES (1) | ES2862912T3 (online.php) |
| HU (1) | HUE054087T2 (online.php) |
| IL (1) | IL235102B (online.php) |
| IN (1) | IN2014DN08812A (online.php) |
| MX (1) | MX359518B (online.php) |
| MY (1) | MY172457A (online.php) |
| NZ (1) | NZ701693A (online.php) |
| PE (1) | PE20150163A1 (online.php) |
| PH (1) | PH12014502347A1 (online.php) |
| PL (1) | PL2839014T3 (online.php) |
| PT (1) | PT2839014T (online.php) |
| RU (1) | RU2683497C2 (online.php) |
| SG (1) | SG11201406776TA (online.php) |
| SI (1) | SI2839014T1 (online.php) |
| WO (1) | WO2013158879A1 (online.php) |
| ZA (1) | ZA201407582B (online.php) |
Families Citing this family (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3085389A1 (en) * | 2005-04-07 | 2016-10-26 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
| HUE030719T2 (en) | 2007-04-09 | 2017-05-29 | Univ Florida | Raav vector compositions having tyrosine-modified capsid proteins and methods for use |
| US9725485B2 (en) | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| KR20140041505A (ko) | 2011-04-29 | 2014-04-04 | 셀렉타 바이오사이언시즈, 인크. | 조절 b 세포 유도를 위한 관용원성 합성 나노운반체 |
| JP6342886B2 (ja) | 2012-04-18 | 2018-06-13 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | Ａａｖカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法 |
| US12358954B2 (en) | 2012-05-15 | 2025-07-15 | University Of Florida Research Foundation, Incorporated | Capsid-modified rAAV vector compositions and methods therefor |
| US10294281B2 (en) | 2012-05-15 | 2019-05-21 | University Of Florida Research Foundation, Incorporated | High-transduction-efficiency rAAV vectors, compositions, and methods of use |
| BR112015027291A8 (pt) | 2013-05-03 | 2019-12-24 | Selecta Biosciences Inc | uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor |
| CN105247044B (zh) * | 2013-05-31 | 2021-05-07 | 加利福尼亚大学董事会 | 腺相关病毒变体及其使用方法 |
| PT3024498T (pt) * | 2013-07-22 | 2020-03-06 | Childrens Hospital Philadelphia | Variante aav e composições, métodos e usos para transferência genética em células, órgãos e tecidos |
| AU2014324717B2 (en) | 2013-09-26 | 2020-10-08 | University Of Florida Research Foundation, Inc. | Synthetic combinatorial AAV capsid library for targeted gene therapy |
| GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| ES2768763T3 (es) * | 2014-03-04 | 2020-06-23 | Univ Florida | Vectores rAAV mejorados y métodos para la transducción de fotorreceptores y células EPR |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| WO2016037164A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
| RU2020140209A (ru) | 2014-10-21 | 2021-01-25 | Юниверсити Оф Массачусетс | Варианты рекомбинантных aav и их применения |
| CN107106689A (zh) | 2014-11-05 | 2017-08-29 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| IL292999A (en) | 2014-11-14 | 2022-07-01 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CN112410338A (zh) | 2014-11-14 | 2021-02-26 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| US20180030096A1 (en) | 2015-02-03 | 2018-02-01 | University Of Florida Research Foundation, Inc. | Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof |
| US10648000B2 (en) | 2015-02-16 | 2020-05-12 | University Of Florida Research Foundation, Incorporated | rAAV vector compositions, methods for targeting vascular endothelial cells and use in treatment of type I diabetes |
| WO2016134337A1 (en) * | 2015-02-19 | 2016-08-25 | University Of Florida Research Foundation, Inc. | Site-specific integrating recombinant aav vectors for gene therapy and improved production methods |
| JP6519080B2 (ja) * | 2015-06-22 | 2019-05-29 | ライオン株式会社 | 繊維製品用抗ウイルス組成物 |
| PT3313991T (pt) | 2015-06-23 | 2024-09-27 | Childrens Hospital Philadelphia | Fator ix modificado e composições, métodos e utilizações para transferência de genes para células, órgãos e tecidos |
| IL314171A (en) | 2015-09-28 | 2024-09-01 | Univ Florida | Methods and compositions for antibody-evading virus vectors |
| US12188037B2 (en) | 2015-10-22 | 2025-01-07 | University Of Florida Research Foundation, Incorporated | Synthetic combinatorial AAV3 capsid library |
| JP2019501115A (ja) | 2015-10-28 | 2019-01-17 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 遺伝子治療のためのアデノ随伴ウイルスベクターのくも膜下腔内投与 |
| PE20231949A1 (es) | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| WO2017096162A1 (en) | 2015-12-02 | 2017-06-08 | Voyager Therapeutics, Inc. | Assays for the detection of aav neutralizing antibodies |
| AU2017248840B2 (en) * | 2016-04-16 | 2022-07-28 | University Of Florida Research Foundation, Incorporated | Methods of enhancing biological potency of baculovirus system-produced recombinant adeno-associated virus |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017197355A2 (en) | 2016-05-13 | 2017-11-16 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
| KR20220108216A (ko) | 2016-05-18 | 2022-08-02 | 보이저 테라퓨틱스, 인크. | 헌팅톤 질환을 치료하기 위한 조성물 및 방법 |
| SG11201809699XA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| SG10201913002QA (en) | 2016-08-15 | 2020-03-30 | Genzyme Corp | Methods for detecting aav |
| CN110650673B (zh) | 2016-08-30 | 2024-04-09 | 加利福尼亚大学董事会 | 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统 |
| CA3040483A1 (en) | 2016-10-13 | 2018-04-19 | University Of Massachusetts | Aav capsid designs |
| WO2018129268A1 (en) | 2017-01-07 | 2018-07-12 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
| EP3575398A4 (en) * | 2017-01-30 | 2020-11-11 | Nippon Medical School Foundation | ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT |
| CA3114549A1 (en) | 2017-02-21 | 2018-08-30 | University Of Florida Research Foundation, Incorporated | Modified aav capsid proteins and uses thereof |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| KR102753928B1 (ko) | 2017-03-11 | 2025-01-14 | 셀렉타 바이오사이언시즈, 인크. | 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물 |
| US10550405B2 (en) | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| IL316259A (en) | 2017-03-15 | 2024-12-01 | Univ North Carolina Chapel Hill | Polyploid gland associated with virus vectors and methods for preparing and using the same. |
| BR112019019813A2 (pt) | 2017-03-30 | 2020-04-22 | The University Of Queensland | moléculas quiméricas e usos das mesmas |
| SG11201909870SA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
| KR20250030036A (ko) | 2017-06-07 | 2025-03-05 | 스파크 테라퓨틱스, 인코포레이티드 | 개선된 세포 트랜스펙션 및/또는 rAAV 벡터 생산을 위한 증진제 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| EP3645052A4 (en) | 2017-06-30 | 2021-07-28 | Regents of the University of California | ADENO-ASSOCIATED VIRUS VIRIONS WITH ASSOCIATED CAPSIDE VARIANTS AND METHODS OF USE |
| JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| EP3687561A4 (en) | 2017-09-01 | 2021-06-09 | The Australian National University | "immunoregulatory molecules and uses therefor" |
| PE20201264A1 (es) | 2017-09-20 | 2020-11-19 | 4D Molecular Therapeutics Inc | Variantes de capsides de virus adenoasociados y metodos de uso de estas |
| MX2020003042A (es) | 2017-09-29 | 2020-11-18 | Voyager Therapeutics Inc | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. |
| MX2020003838A (es) | 2017-10-13 | 2020-08-06 | Selecta Biosciences Inc | Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral. |
| EP4454654A3 (en) | 2017-10-16 | 2025-02-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| US11434502B2 (en) | 2017-10-16 | 2022-09-06 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
| ES2946747T3 (es) | 2017-11-27 | 2023-07-25 | 4D Molecular Therapeutics Inc | Variantes de cápsides de virus adenoasociado y su utilización para inhibir la angiogénesis |
| CN111727243A (zh) | 2017-12-19 | 2020-09-29 | 北卡罗来纳-查佩尔山大学 | 用于跨越血-脑屏障递送病毒载体的方法和组合物 |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| AU2019215152A1 (en) | 2018-02-01 | 2020-08-20 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof |
| JP7244547B2 (ja) | 2018-02-19 | 2023-03-22 | ホモロジー・メディシンズ・インコーポレイテッド | Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法 |
| KR20200139679A (ko) | 2018-02-26 | 2020-12-14 | 안톨알엑스, 인크. | 면역관용성 리포솜 및 그의 사용 방법 |
| IL276859B2 (en) * | 2018-02-27 | 2025-12-01 | Univ Pennsylvania | Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor |
| KR20250111393A (ko) * | 2018-03-16 | 2025-07-22 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 캡시드 변형에 의한 증가하는 조직 특정 유전자 전달 |
| WO2019195444A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
| JP7406677B2 (ja) | 2018-04-03 | 2023-12-28 | ギンコ バイオワークス インコーポレイテッド | 抗体を回避するウイルスベクター |
| WO2019195423A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| CN112004925B (zh) | 2018-04-05 | 2024-09-27 | 吉尼松公司 | 具有降低的肝向性的AAV9和AAVrh74的杂合重组腺相关病毒血清型 |
| EP3784697A4 (en) * | 2018-04-27 | 2022-07-06 | Spark Therapeutics, Inc. | GMO AAV CAPSIDS WITH INCREASED TROPISM AND AAV VECTORS CONTAINING THE GMO CAPSIDS, AND METHODS FOR THEIR MANUFACTURE AND USE |
| CN119410636A (zh) | 2018-04-27 | 2025-02-11 | 分贝治疗公司 | 肌球蛋白15启动子及其用途 |
| EP3794126A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| CN112334489A (zh) * | 2018-05-16 | 2021-02-05 | 星火治疗有限公司 | 密码子优化的酸性α-葡萄糖苷酶表达盒及其使用方法 |
| EP3823676A1 (en) | 2018-07-16 | 2021-05-26 | Selecta Biosciences, Inc. | Methods and compositions of mma constructs and vectors |
| JP2021531282A (ja) | 2018-07-16 | 2021-11-18 | セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences, Inc. | Ｏｔｃコンストラクトおよびベクターの方法および組成物 |
| CN113383010B (zh) | 2018-09-28 | 2025-09-09 | 沃雅戈治疗公司 | 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法 |
| KR20210082460A (ko) | 2018-10-01 | 2021-07-05 | 울트라제닉스 파마수티컬 인코포레이티드 | 프로피온산혈증을 치료하기 위한 유전자 요법 |
| BR112021007301A2 (pt) | 2018-10-18 | 2021-07-27 | Intellia Therapeutics, Inc. | composições e métodos para expressar fator ix |
| US11702673B2 (en) | 2018-10-18 | 2023-07-18 | University Of Florida Research Foundation, Incorporated | Methods of enhancing biological potency of baculovirus system-produced recombinant adeno-associated virus |
| EP3921032A4 (en) | 2019-02-08 | 2022-11-30 | Decibel Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS |
| JP7562544B2 (ja) | 2019-02-08 | 2024-10-07 | デシベル セラピューティクス インコーポレイテッド | ミオシン１５プロモーター及びその使用 |
| SG11202108044YA (en) | 2019-02-25 | 2021-09-29 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
| WO2020174369A2 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
| AR118465A1 (es) | 2019-03-21 | 2021-10-06 | Stridebio Inc | Vectores de virus adenoasociados recombinantes |
| BR112021021566A2 (pt) | 2019-04-28 | 2022-04-19 | Selecta Biosciences Inc | Métodos para tratamento de indivíduos com imunidade preexistente a vetores de transferência viral |
| BR112021023594A2 (pt) | 2019-05-28 | 2022-02-08 | Selecta Biosciences Inc | Métodos e composições para resposta imune de vetor de transferência antiviral atenuada |
| EP3980784A1 (en) | 2019-06-04 | 2022-04-13 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
| RU2751592C2 (ru) | 2019-08-22 | 2021-07-15 | Общество С Ограниченной Ответственностью "Анабион" | Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе |
| US12544437B2 (en) | 2019-10-04 | 2026-02-10 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant AAV |
| KR20220083708A (ko) | 2019-10-17 | 2022-06-20 | 스트라이드바이오 인코포레이티드 | Aav 전달 카세트 |
| AU2020367532A1 (en) | 2019-10-17 | 2022-05-12 | Ginkgo Bioworks, Inc. | Adeno-associated viral vectors for treatment of Niemann-Pick disease type C |
| JP7665609B2 (ja) | 2019-10-30 | 2025-04-21 | デシベル セラピューティクス インコーポレイテッド | オトフェリン二重ベクター系及びそれを含む感音難聴を治療するための組成物 |
| KR20220121823A (ko) | 2020-01-03 | 2022-09-01 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Aav 캡시드 단백질을 분석하기 위한 방법 |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| BR112022015921A2 (pt) | 2020-02-14 | 2022-10-04 | Ultragenyx Pharmaceutical Inc | Terapia gênica para tratar o transtorno de deficiência de cdkl5 |
| JP2023518415A (ja) | 2020-03-19 | 2023-05-01 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | 組換えａａｖにおいてｃａｐおよびｒｅｐ配列の逆パッケージングを低減するための組成物および方法 |
| US20230129893A1 (en) | 2020-03-31 | 2023-04-27 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating propionic acidemia |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| MX2023002016A (es) | 2020-08-19 | 2023-06-26 | Sarepta Therapeutics Inc | Vectores de virus adenoasociados para el tratamiento del sindrome de rett. |
| EP4229204A1 (en) | 2020-10-15 | 2023-08-23 | F. Hoffmann-La Roche AG | Nucleic acid constructs for simultaneous gene activation |
| KR20230085929A (ko) | 2020-10-15 | 2023-06-14 | 에프. 호프만-라 로슈 아게 | Va rna 전사를 위한 핵산 구조체 |
| AU2022206197A1 (en) | 2021-01-05 | 2023-07-13 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| AU2022262407A1 (en) * | 2021-04-23 | 2023-10-26 | University Of Florida Research Foundation, Incorporated | Aavrh74 vectors for gene therapy of muscular dystrophies |
| JP2024531138A (ja) | 2021-08-11 | 2024-08-29 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | 筋ジストロフィーを処置するための組成物および方法 |
| AR126839A1 (es) | 2021-08-20 | 2023-11-22 | Llc «Anabion» | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta |
| AR126840A1 (es) | 2021-08-20 | 2023-11-22 | Llc «Anabion» | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta |
| MA64631B1 (fr) | 2021-08-20 | 2024-12-31 | Joint Stock Company "Biocad" | Procédé de production de capside modifié de virus adéno-associé |
| WO2023044306A1 (en) * | 2021-09-14 | 2023-03-23 | California Institute Of Technology | Aav capsid variants |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| JP2024539646A (ja) | 2021-10-12 | 2024-10-29 | カーティザン セラピューティクス，インコーポレーテッド | ウイルスベクター投薬プロトコル |
| WO2023086615A1 (en) | 2021-11-14 | 2023-05-19 | Selecta Biosciences, Inc. | Multiple dosing with viral vectors |
| CN116554278A (zh) * | 2022-01-30 | 2023-08-08 | 上海玮美基因科技有限责任公司 | 变异型腺相关病毒及其在疾病治疗中的应用 |
| JP2025509328A (ja) | 2022-03-07 | 2025-04-11 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | 改良されたバッチａａｖ産生システムおよび方法 |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| WO2023198685A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Method for determining aav genomes |
| JP2025516583A (ja) * | 2022-05-11 | 2025-05-30 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | 脳深部構造を標的とするアデノ随伴ウイルスベクター |
| CN119256220A (zh) | 2022-05-23 | 2025-01-03 | 豪夫迈·罗氏有限公司 | 用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法 |
| EP4532737A1 (en) | 2022-06-03 | 2025-04-09 | F. Hoffmann-La Roche AG | Method for producing recombinant aav particles |
| KR20250036743A (ko) | 2022-07-14 | 2025-03-14 | 에프. 호프만-라 로슈 아게 | 재조합 aav 입자를 생산하는 방법 |
| CA3264659A1 (en) | 2022-08-11 | 2024-02-15 | Cartesian Therapeutics, Inc. | COMPOSITIONS AND PROCESSES ASSOCIATED WITH IMMUNOGLOBULIN PROTEASES AND FUSION THEREOF |
| KR20250050869A (ko) | 2022-08-15 | 2025-04-15 | 에프. 호프만-라 로슈 아게 | 재조합 바이러스 벡터와 관련된 부작용의 예방 또는 완화 |
| EP4744752A1 (en) | 2022-09-12 | 2026-05-20 | Hoffmann La Roche | METHOD FOR SEPARING SOLID AND EMPTY AAV PARTICLES |
| IL322001A (en) | 2023-02-07 | 2025-09-01 | Hoffmann La Roche | Method for detecting antibodies to anti-AAV particles |
| EP4683676A1 (en) | 2023-03-21 | 2026-01-28 | F. Hoffmann-La Roche AG | Method for the production of recombinant aav particle preparations |
| CN120936723A (zh) | 2023-04-13 | 2025-11-11 | 豪夫迈·罗氏有限公司 | 改进的重组多腺苷酸化信号序列及其用途 |
| WO2025057182A1 (en) * | 2023-09-15 | 2025-03-20 | Indian Institute Of Technology Kanpur | Modified aav vectors for enhanced gene therapy in hemophilia b |
| WO2025082618A1 (en) | 2023-10-20 | 2025-04-24 | Fuse Vectors Aps | In vitro parvovirus capsid manufacturing |
| WO2025168663A1 (en) | 2024-02-09 | 2025-08-14 | F. Hoffmann-La Roche Ag | Method for producing recombinant adeno-associated viral particles |
| WO2025252480A1 (en) | 2024-06-07 | 2025-12-11 | F. Hoffmann-La Roche Ag | Method for purifying plasmid dna |
| WO2026022064A1 (en) | 2024-07-22 | 2026-01-29 | F. Hoffmann-La Roche Ag | Novel aav rep orfs and rep polypeptides |
| WO2026037757A1 (en) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | Modified aav particles |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1202962A (en) | 1982-10-19 | 1986-04-08 | David P. Clifford | Substituted n-phenyl-n'-benzoyl ureas and their use as insecticides and acaricides |
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| JP2001500015A (ja) | 1996-09-06 | 2001-01-09 | トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法 |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| JP4888876B2 (ja) * | 2003-06-13 | 2012-02-29 | 田平 武 | アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター |
| EP3085389A1 (en) * | 2005-04-07 | 2016-10-26 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
| US9198984B2 (en) | 2006-04-28 | 2015-12-01 | The Trustees Of The University Of Pennsylvania | Scalable production method for AAV |
| KR20130040844A (ko) | 2010-03-29 | 2013-04-24 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 약학적으로 유발된 전이유전자 제거 시스템 |
| WO2013078316A1 (en) | 2011-11-23 | 2013-05-30 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| JP6342886B2 (ja) | 2012-04-18 | 2018-06-13 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | Ａａｖカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法 |
-
2013
- 2013-04-18 JP JP2015507176A patent/JP6342886B2/ja active Active
- 2013-04-18 CN CN201380020980.5A patent/CN104487579B/zh active Active
- 2013-04-18 DK DK13778449.2T patent/DK2839014T3/da active
- 2013-04-18 BR BR122021020419-5A patent/BR122021020419B1/pt active IP Right Grant
- 2013-04-18 IN IN8812DEN2014 patent/IN2014DN08812A/en unknown
- 2013-04-18 CA CA2870736A patent/CA2870736C/en active Active
- 2013-04-18 KR KR1020147032322A patent/KR102063483B1/ko active Active
- 2013-04-18 MX MX2014012680A patent/MX359518B/es active IP Right Grant
- 2013-04-18 SI SI201331862T patent/SI2839014T1/sl unknown
- 2013-04-18 WO PCT/US2013/037170 patent/WO2013158879A1/en not_active Ceased
- 2013-04-18 MY MYPI2014002969A patent/MY172457A/en unknown
- 2013-04-18 AU AU2013249202A patent/AU2013249202B2/en active Active
- 2013-04-18 US US14/394,454 patent/US9909142B2/en active Active
- 2013-04-18 SG SG11201406776TA patent/SG11201406776TA/en unknown
- 2013-04-18 PT PT137784492T patent/PT2839014T/pt unknown
- 2013-04-18 PL PL13778449T patent/PL2839014T3/pl unknown
- 2013-04-18 EP EP13778449.2A patent/EP2839014B1/en active Active
- 2013-04-18 NZ NZ701693A patent/NZ701693A/en unknown
- 2013-04-18 HU HUE13778449A patent/HUE054087T2/hu unknown
- 2013-04-18 BR BR112014025985A patent/BR112014025985A2/pt not_active Application Discontinuation
- 2013-04-18 RU RU2014146159A patent/RU2683497C2/ru active
- 2013-04-18 PE PE2014001722A patent/PE20150163A1/es active IP Right Grant
- 2013-04-18 ES ES13778449T patent/ES2862912T3/es active Active
-
2014
- 2014-10-17 ZA ZA2014/07582A patent/ZA201407582B/en unknown
- 2014-10-19 IL IL235102A patent/IL235102B/en active IP Right Grant
- 2014-10-20 PH PH12014502347A patent/PH12014502347A1/en unknown
- 2014-11-18 CO CO14253041A patent/CO7200251A2/es unknown
-
2018
- 2018-02-02 US US15/887,641 patent/US11279950B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY172457A (en) | Composition and methods for highly efficient gene transfer using aav capsid variants | |
| PH12020551744A1 (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| EA201591992A1 (ru) | Эффективная доставка больших генов посредством двойных aav векторов | |
| PH12018501055A1 (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
| MX2022006652A (es) | Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus. | |
| WO2011133890A8 (en) | Cns targeting aav vectors and methods of use thereof | |
| MX2014009975A (es) | Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos. | |
| WO2012112578A3 (en) | Improved aav8 vector with enhanced functional activity and methods of use thereof | |
| EA201001491A1 (ru) | Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов | |
| WO2010138263A3 (en) | Novel aav 's and uses thereof | |
| EP4089172A3 (en) | Multiple vector system and uses thereof | |
| MX371018B (es) | Polipéptidos que tienen actividad de transgalactosilación. | |
| EP3845552A3 (en) | High-transduction-efficiency raav vectors, compositions, and methods of use | |
| MX344972B (es) | Oligonucleotidos inmunoestimulantes. | |
| PH12015502126A1 (en) | Human pac1 antibodies | |
| MX2018000470A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22). | |
| MY173686A (en) | Fc gamma receptor iib variants | |
| WO2011098778A8 (en) | Peptides for vaccines against birch allergy | |
| WO2012090207A3 (en) | Par1 and par2 c-tail peptides and peptide mimetics | |
| HK1206385A1 (zh) | 具有改变的末端的成批重组腺病毒 | |
| MY205057A (en) | Varian aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2019 BY CPA GLOBAL Effective date: 20180302 |
|
| S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended | ||
| S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2020 BY CPA GLOBAL Effective date: 20190307 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2021 BY CPA GLOBAL Effective date: 20200306 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2022 BY CPA GLOBAL Effective date: 20210305 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2023 BY CPA GLOBAL Effective date: 20220304 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2024 BY CPA GLOBAL Effective date: 20230303 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240307 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250307 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2027 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20260305 |